H
Heiner Wedemeyer
Researcher at Hannover Medical School
Publications - 32
Citations - 12251
Heiner Wedemeyer is an academic researcher from Hannover Medical School. The author has contributed to research in topics: Hepatitis C virus & Cytotoxic T cell. The author has an hindex of 29, co-authored 32 publications receiving 11247 citations. Previous affiliations of Heiner Wedemeyer include Hochschule Hannover & Leibniz University of Hanover.
Papers
More filters
Journal ArticleDOI
Global prevalence and genotype distribution of hepatitis C virus infection in 2015: a modelling study
Sarah Blach,Stefan Zeuzem,Michael Manns,Ibrahim Altraif,Ann-Sofi Duberg,David H. Muljono,Imam Waked,Seyed M Alavian,Mei Hsuan Lee,Francesco Negro,Faisal Abaalkhail,Ahmed Abdou,Maheeba Abdulla,Antoine Abou Rached,Inka Aho,Ulus Salih Akarca,Imad Al Ghazzawi,Saad Al Kaabi,Faryal Al Lawati,Khalid Al Namaani,Youssif Al Serkal,Said A. Al-Busafi,Layla Al-Dabal,Soo Aleman,Abdullah S. Alghamdi,Abdulrahman Aljumah,Hamad Al-Romaihi,Monique Andersson,Vic Arendt,Perttu Arkkila,Abdullah M. Assiri,Oidov Baatarkhuu,Abate Bane,Ziv Ben-Ari,Colm Bergin,Fernando Bessone,Florian Bihl,Abdul Rahman Bizri,M. Blachier,Antonio Javier Blasco,Carlos E Brandão Mello,Philip Bruggmann,Cheryl Brunton,Filipe Calinas,Henry Lik-Yuen Chan,Asad Chaudhry,Hugo Cheinquer,Chien-Jen Chen,Rong-Nan Chien,Moon Seok Choi,Peer Brehm Christensen,Wan-Long Chuang,Vladimir Chulanov,Laura Cisneros,Mette Rye Clausen,Matthew E. Cramp,Antonio Craxì,E. A. Croes,Olav Dalgard,Jorge Daruich,Victor de Ledinghen,Gregory J. Dore,Manal H El-Sayed,Gül Ergör,Gamal Esmat,Chris Estes,Karolin Falconer,Elmoubashar Farag,Maria Lucia Gomes Ferraz,Paulo R. Ferreira,Robert Flisiak,Sona Frankova,Ivane Gamkrelidze,Edward Gane,Javier García-Samaniego,Akram Khan,Ilias Gountas,Adrian Goldis,Magnus Gottfredsson,Jason Grebely,Michael Gschwantler,Mario G. Pessoa,Jessie Gunter,Behzad Hajarizadeh,Omer Hajelssedig,Saeed Hamid,Waseem Hamoudi,Angelos Hatzakis,Sayed Himatt,Harald Hofer,Irena Hrstić,Yee Tak Hui,Béla Hunyady,Ramazan Idilman,Wasim Jafri,Rohani Jahis,Naveed Z. Janjua,Peter Jarcuska,Agita Jeruma,Jon G. Jonasson,Yasser Kamel,Jia-Horng Kao,Sabahattin Kaymakoglu,David Kershenobich,Jawad Khamis,Young Sik Kim,Loreta A. Kondili,Zaher Koutoubi,Mel Krajden,Henrik Krarup,Moon sing Lai,Wim Laleman,Wai-cheung C Lao,Daniel Lavanchy,Pablo Lázaro,Henri Leleu,Olufunmilayo A. Lesi,Laurentius A. Lesmana,Michael Li,Valentina Liakina,Young-Suk Lim,Boris Lukšić,Adam Mahomed,Matti Maimets,Mihály Makara,Abraham O. Malu,Rui Tato Marinho,Paul Marotta,Stefan Mauss,Muhammad S. Memon,Maria C Mendes Correa,Nahum Méndez-Sánchez,Shahin Merat,Ammal M. Metwally,Rosmawati Mohamed,Christophe Moreno,Fadi H. Mourad,Beat Müllhaupt,Kimberly Murphy,Helen Nde,Richard Njouom,Diana Nonković,Suzanne Norris,Solomon Obekpa,Stephen Oguche,S. Olafsson,Marian Oltman,Ogu Omede,CE Omuemu,Ohene Opare-Sem,Anne Øvrehus,Shirley Owusu-Ofori,Tsendsuren S. Oyunsuren,George V. Papatheodoridis,Ken Pasini,Kevork M. Peltekian,Richard Phillips,N. N. Pimenov,Hossein Poustchi,Nishi Prabdial-Sing,Huma Qureshi,Alnoor Ramji,Devin Razavi-Shearer,Kathryn Razavi-Shearer,Berhane Redae,Henk W. Reesink,Ezequiel Ridruejo,Sarah Robbins,Lewis R. Roberts,Stuart K. Roberts,William Rosenberg,Françoise Roudot-Thoraval,Stephen D. Ryder,Rifaat Safadi,Olga Sagalova,Riina Salupere,Faisal M. Sanai,Juan F.Sanchez Avila,Vivek A. Saraswat,Rui Sarmento-Castro,Christoph Sarrazin,Jonathan Schmelzer,Ivan Schréter,Carole Seguin-Devaux,Samir Shah,Ala I. Sharara,Manik Sharma,Anatoly Shevaldin,Gamal Shiha,William Sievert,Mark W. Sonderup,Kyriakos Souliotis,Danute Speiciene,Jan Sperl,Peter Stärkel,Rudolf E. Stauber,Catherine A.M. Stedman,Daniel Struck,Tung-Hung Su,Vana Sypsa,Soek Siam Tan,Junko Tanaka,Alexander J. Thompson,Ieva Tolmane,Krzysztof Tomasiewicz,Jonas Valantinas,Pierre Van Damme,Adriaan J. van der Meer,Ingo van Thiel,Hans Van Vlierberghe,Adriana Vince,Wolfgang Vogel,Heiner Wedemeyer,Nina Weis,Vincent Ws Wong,Cesar Yaghi,Ayman Yosry,Man-Fung Yuen,Evy Yunihastuti,Aasim Yusuf,Eli Zuckerman,Homie Razavi +221 more
TL;DR: The global estimate of viraemic HCV infections is lower than previous estimates, largely due to more recent prevalence estimates in Africa, and increased mortality due to liver-related causes and an ageing population may have contributed to a reduction in infections.
Journal ArticleDOI
Association between sustained virological response and all-cause mortality among patients with chronic hepatitis C and advanced hepatic fibrosis.
Adriaan J. van der Meer,Bart J. Veldt,Jordan J. Feld,Heiner Wedemeyer,Jean-François Dufour,Frank Lammert,Andres Duarte-Rojo,E. Jenny Heathcote,Michael P. Manns,L. Kuske,Stefan Zeuzem,W. Peter Hofmann,Robert J. de Knegt,Bettina E. Hansen,Harry L.A. Janssen +14 more
TL;DR: Among patients with chronic HCV infection and advanced hepatic fibrosis, sustained virological response to interferon-based treatment was associated with lower all-cause mortality.
Journal ArticleDOI
ABT-450/r-Ombitasvir and Dasabuvir with Ribavirin for Hepatitis C with Cirrhosis
Fred Poordad,Christophe Hézode,Roger Trinh,Kris V. Kowdley,Stefan Zeuzem,Kosh Agarwal,Mitchell L. Shiffman,Heiner Wedemeyer,Thomas Berg,Eric M. Yoshida,Xavier Forns,Sandra S. Lovell,Barbara Da Silva-Tillmann,Christine Collins,Campbell Andrew L,Thomas Podsadecki,B. Bernstein +16 more
TL;DR: In this phase 3 trial of an oral, interferon-free regimen evaluated exclusively in patients with HCV genotype 1 infection and cirrhosis, multitargeted therapy with the use of three new antiviral agents and ribavirin resulted in high rates of sustained virology response.
Journal ArticleDOI
Treatment of Acute Hepatitis C with Interferon Alfa-2b
Elmar Jaeckel,Markus Cornberg,Heiner Wedemeyer,T Santantonio,John E. Mayer,M Zankel,G Pastore,M. Dietrich,C Trautwein,Michael P. Manns +9 more
TL;DR: Treatment of acute hepatitis C with interferon alfa-2b with treatment during the acute phase could prevent the development of chronic infection.
Journal ArticleDOI
Treating viral hepatitis C: efficacy, side effects, and complications
TL;DR: The efficacy and optimisation of the current standard therapy of hepatitis C and its problems in special patient populations are described.